3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Withdrawn
1
Terminated
1
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Gastrointestinal
1
Conditions
Carcinoma, Renal Cell
46
Sarcoma
21
Neoplasms
18
Neoplasm Metastasis
15
Ovarian Neoplasms
12
Breast Neoplasms
10
Carcinoma, Non-Small-Cell Lung
8
Recurrence
5
Melanoma
5
Fallopian Tube Neoplasms
5
Thyroid Neoplasms
4
Prostatic Neoplasms
4
Liposarcoma
4
Hemangiosarcoma
4
Urinary Bladder Neoplasms
3
Solid Tumors
3
Lung Neoplasms
3
Leiomyosarcoma
3
Kidney Neoplasms
3
Glioblastoma
3
Colorectal Neoplasms
3
Clear-cell metastatic renal cell carcinoma
3
Carcinoma, Ovarian Epithelial
3
Thyroid Carcinoma, Anaplastic
2
Sarcoma, Synovial
2
Refractory Solid Tumors
2
Neuroendocrine Tumors
2
Gliosarcoma
2
Financial Stress
2
Chondrosarcoma, Extraskeletal Myxoid
2
Interventions
Imatinib Mesylate
41
Sunitinib
17
nilotinib
12
regorafenib
10
ripretinib
6
avapritinib
6
Leucovorin
3
Ipilimumab
3
Gemcitabine
3
Dasatinib
3
CTLA-4 Antigen
3
4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one
3
pexidartinib
2
Paclitaxel
2
Oxaliplatin
2
Midazolam
2
Irinotecan
2
Fluorouracil
2
Floxuridine
2
Erlotinib Hydrochloride
2
Docetaxel
2
Cisplatin
2
Carboplatin
2
Capecitabine
2
Biopsy, Fine-Needle
2
Bevacizumab
2
vatalanib
1
umbralisib
1
trametinib
1
tinostamustine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Gastrointestinal Stromal Tumors
×
pazopanib
×
Clear all
NCT01524848
2017-05-10
PAGIST
Scandinavian Sarcoma Group
Phase 2
Completed
72 enrolled